

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

CanSino Biologics Inc.
康希諾生物股份公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 6185)

INSIDE INFORMATION
USING RESERVES TO OFFSET LOSSES

This announcement is made by CanSino Biologics Inc. (the “**Company**”) pursuant to Rule 13.09 (2) and 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571, Laws of Hong Kong).

In order to proactively promote the Company’s high-quality development and enhance its capacity to deliver investor returns, the Company proposed to use reserves to offset the accumulated losses as of December 31, 2024 in accordance with the relevant laws and regulations.

At the third extraordinary meeting of the third session of the Board of Directors held by the Company on November 7, 2025, the Proposal on the Use of Reserves to Offset Losses was reviewed and approved. The proposal is subject to the approval of the Shareholders at the 2025 second extraordinary general meeting (the “**EGM**”) by way of ordinary resolution. Details are hereby announced as follows:

BASIC INFORMATION FOR USING RESERVES TO OFFSET LOSSES

According to the 2024 Annual Financial Statements and Audit Report of the Company issued by Deloitte Touche Tohmatsu Certified Public Accountants (LLP), as of December 31, 2024, the parent company’s accumulated losses amounted to RMB1,450,342,128.90, its surplus reserve amounted to RMB118,388,703.29, and its capital reserve amounted to RMB6,576,729,725.03.

The parent company’s accumulated losses were mainly attributable to the operating results of prior years. The portion of the capital reserve proposed to be used to offset the accumulated losses is entirely derived from share premium formed by cash contributions from shareholders.

PROPOSED SCHEME FOR COVERING ACCUMULATED LOSSES

In accordance with the Company Law of the People's Republic of China, the Ministry of Finance's Notice on Financial Treatment Issues Following the Implementation of the Company Law and the Foreign Investment Law (《關於公司法、外商投資法施行後有關財務處理問題的通知》), and other relevant laws, regulations and regulatory documents, as well as the provisions of the Articles of Association of CanSino Biologics Inc., the Company proposed to use the parent company's surplus reserve of RMB118,388,703.29 and capital reserve of RMB1,331,953,425.61, totaling RMB1,450,342,128.90, to offset the accumulated losses of the parent company. This utilization of reserves will be limited to reducing the parent company's accumulated losses as of year-end 2024 to zero.

IMPACTS ON THE COMPANY

Upon completion of the plan to offset losses, the parent company's surplus reserve will be reduced to RMB0, capital reserve will be reduced to RMB5,244,776,299.42, and the accumulated losses will be fully offset to RMB0 as of December 31, 2024. The implementation of the plan to use reserves to offset the accumulated losses as of December 31, 2024 will enable the Company to enhance its capacity to deliver investor returns and support the Company's high-quality development.

PROCEDURES OF CONSIDERATION

An ordinary resolution will be proposed at the EGM to consider and approve the proposed utilization of reserves to offset losses by the Company. Investors are advised to pay attention to the investment risks.

By order of the Board
CanSino Biologics Inc.
Xuefeng YU
Chairman

Hong Kong, November 7, 2025

As of the date of this announcement, the board of directors of the Company comprises Dr. Xuefeng YU, Dr. Shou Bai CHAO and Ms. Jing WANG as executive Directors, Mr. Chi Shing LI as a non-executive Director, and Mr. Shuifa GUI, Mr. Jianzhong LIU and Mr. Yiu Leung Andy CHEUNG as independent non-executive Directors.